PL2739623T3 - Inhibitory replikacji wirusów grypy - Google Patents

Inhibitory replikacji wirusów grypy

Info

Publication number
PL2739623T3
PL2739623T3 PL12746215T PL12746215T PL2739623T3 PL 2739623 T3 PL2739623 T3 PL 2739623T3 PL 12746215 T PL12746215 T PL 12746215T PL 12746215 T PL12746215 T PL 12746215T PL 2739623 T3 PL2739623 T3 PL 2739623T3
Authority
PL
Poland
Prior art keywords
inhibitors
influenza viruses
viruses replication
replication
influenza
Prior art date
Application number
PL12746215T
Other languages
English (en)
Polish (pl)
Inventor
Paul S. Charifson
Michael P. Clark
Upul K. Bandarage
Randy S. Bethiel
Michael J. Boyd
Ioana Davies
Hongbo Deng
John P. Duffy
Luc J. Farmer
Huai Gao
Wenxin Gu
Joseph M. Kennedy
Brian Ledford
Mark W. Ledeboer
Francois Maltais
Emanuele Perola
Tiansheng Wang
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46650922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2739623(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of PL2739623T3 publication Critical patent/PL2739623T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL12746215T 2011-08-01 2012-08-01 Inhibitory replikacji wirusów grypy PL2739623T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513793P 2011-08-01 2011-08-01
EP12746215.8A EP2739623B1 (en) 2011-08-01 2012-08-01 Inhibitors of influenza viruses replication

Publications (1)

Publication Number Publication Date
PL2739623T3 true PL2739623T3 (pl) 2017-07-31

Family

ID=46650922

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12746215T PL2739623T3 (pl) 2011-08-01 2012-08-01 Inhibitory replikacji wirusów grypy

Country Status (37)

Country Link
US (5) US9051319B2 (https=)
EP (2) EP3147284B1 (https=)
JP (3) JP5917692B2 (https=)
KR (1) KR101967172B1 (https=)
CN (3) CN103764654B (https=)
AP (1) AP3867A (https=)
AR (1) AR087418A1 (https=)
AU (2) AU2012290127B2 (https=)
CA (1) CA2844054C (https=)
CL (1) CL2014000245A1 (https=)
CO (1) CO6940412A2 (https=)
CY (1) CY1118726T1 (https=)
DK (1) DK2739623T3 (https=)
EA (3) EA023423B1 (https=)
EC (1) ECSP14013189A (https=)
ES (2) ES2763535T3 (https=)
GE (2) GEP201706698B (https=)
HK (1) HK1223915A1 (https=)
HR (1) HRP20170421T1 (https=)
HU (1) HUE033752T2 (https=)
IL (2) IL230618A (https=)
IN (1) IN2014CN00562A (https=)
LT (1) LT2739623T (https=)
ME (1) ME02638B (https=)
MX (1) MX339149B (https=)
PE (1) PE20141209A1 (https=)
PH (1) PH12014500257A1 (https=)
PL (1) PL2739623T3 (https=)
PT (1) PT2739623T (https=)
RS (1) RS55858B1 (https=)
SG (2) SG10201503835TA (https=)
SI (1) SI2739623T1 (https=)
TW (3) TWI594997B (https=)
UA (2) UA118010C2 (https=)
UY (1) UY34234A (https=)
WO (1) WO2013019828A1 (https=)
ZA (2) ZA201400604B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2354140A1 (en) * 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
JP2011513483A (ja) * 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
LT3141252T (lt) 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
NZ714502A (en) 2011-07-05 2017-04-28 Vertex Pharma Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
JP6618901B2 (ja) * 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
CN103922966B (zh) * 2014-04-14 2015-10-21 武汉大学 作为甲型流感病毒抑制剂的甲酰胺和异腈类化合物及其制备与应用
CN106573920B (zh) * 2014-08-08 2020-11-10 爱尔兰詹森科学公司 用于在流感病毒感染中使用的吲哚
ES2860688T3 (es) * 2014-09-08 2021-10-05 Janssen Sciences Ireland Uc Pirrolopirimidinas para uso en la infección por el virus de la gripe
MA40772A (fr) * 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3294735B8 (en) * 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6903658B2 (ja) 2015-11-27 2021-07-14 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー インフルエンザウィルス感染に使用するための複素環インドール
SG11201804225PA (en) 2015-12-09 2018-06-28 Sunshine Lake Pharma Co Ltd Inhibitors of influenza virus replication, application methods and uses thereof
DK3400225T3 (da) * 2016-01-07 2022-01-03 Janssen Sciences Ireland Unlimited Co Pentansyrederivater substitueret med pyrrolo-[2,3-b]pyrimidinpyridiner til behandling af influenzavirusinfektioner
MX381314B (es) 2016-01-20 2025-03-12 Janssen Sciences Ireland Uc Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza
KR102598246B1 (ko) * 2016-07-26 2023-11-02 톈진 롱보진 파마시우티컬 씨오., 엘티디. Jak 저해제로서 헤테로사이클릭 화합물, 및 이의 염 및 치료학적 용도
WO2018033082A1 (en) 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2018041091A1 (en) * 2016-08-30 2018-03-08 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN106478460B (zh) * 2016-09-28 2018-06-12 衢州学院 一种手性N-Boc-3-氨基-4-芳基-丁酸的合成方法
JP7034162B2 (ja) 2016-12-15 2022-03-11 サンシャイン・レイク・ファーマ・カンパニー・リミテッド インフルエンザウイルス複製の阻害剤及びその使用
CN108276401B (zh) * 2017-01-05 2020-12-22 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2018157830A1 (en) 2017-03-02 2018-09-07 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN111511907A (zh) 2017-03-14 2020-08-07 加利福尼亚大学董事会 对病毒中免疫逃逸功能区域的全基因组鉴定
CN109384783A (zh) * 2017-08-09 2019-02-26 银杏树药业(苏州)有限公司 新型杂环化合物及其作为抗流感病毒抑制剂的医药用途
EP3829719B1 (en) 2018-07-27 2025-04-02 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
CN112979647B (zh) * 2021-03-12 2022-05-20 浙江大学 含氮杂氨基酸的氮杂吲哚衍生物及制备和应用

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349552A (en) 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
NZ221717A (en) 1986-09-10 1990-08-28 Sandoz Ltd Azaindole and indolizine derivatives and pharmaceutical compositions
MX19185A (es) 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
JPH10510510A (ja) 1994-06-09 1998-10-13 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
ES2219302T3 (es) 1999-01-07 2004-12-01 Wyeth Derivados de arilpiperazinil-ciclohexilindol para el tratamiento de la depresion.
AU2494300A (en) 1999-01-07 2000-07-24 American Home Products Corporation 3,4-dihydro-2h-benzo(1,4)oxazine derivatives
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
AR028475A1 (es) 1999-04-22 2003-05-14 Wyeth Corp Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
US20030153560A1 (en) 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
ES2260033T3 (es) 1999-07-02 2006-11-01 Stuart A. Lipton Uso de los inhibidores p38 mapk en efermadades oftalmicas.
GB9919843D0 (en) 1999-08-20 1999-10-27 Smithkline Beecham Plc Novel compounds
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
EP1246823A1 (en) 1999-12-28 2002-10-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
US7041277B2 (en) 2000-03-10 2006-05-09 Cadbury Adams Usa Llc Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
HK1052705B (en) 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
PT1315492E (pt) 2000-09-06 2008-10-01 Ortho Mcneil Pharm Inc Utilização de pirazoles substituídos para o tratamento de alergias
US6369032B1 (en) 2000-09-06 2002-04-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
WO2002051837A2 (en) 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
ATE497603T1 (de) 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
SI1392697T1 (en) 2001-03-14 2005-02-28 Wyeth Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-dioxino 2,3-f)quinoline
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US6559169B2 (en) 2001-04-24 2003-05-06 Wyeth Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-benzodioxan
US6656950B2 (en) 2001-04-25 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
ES2247327T3 (es) 2001-04-26 2006-03-01 Wyeth Derivados azaheterociclimetilicos antidepresivos (isrs) de 7,8-dihidro-3h-6,9-dioxa-1,3-diazaciclopenta(a) naftaleno.
US6656947B2 (en) 2001-04-26 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline
JP2004527563A (ja) 2001-04-26 2004-09-09 ワイス 抗うつ作用を有する、２，３−ジヒドロ−１，４−ジオキシノ［２，３−ｆ］キノキサリンのアザへテロシクリルメチル誘導体
ES2229138T3 (es) 2001-04-26 2005-04-16 Wyeth Derivados antidepresivos azaheterociclilmetilicos de (1,4)- benzodiaxanos condensados con oxaheterociclos.
US6593350B2 (en) 2001-04-26 2003-07-15 Wyeth Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
US6555560B2 (en) 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
BR0209407A (pt) 2001-04-30 2004-07-06 Wyeth Corp Antidepressivos de azaheterociclilmetila derivados de 7,8-dihidro-1,6,9-trioxa-3-aza-ciclopenta[a[]naftaleno , método de tratamento usando tais compostos e processo para prepará-los
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
MXPA03010524A (es) 2001-05-17 2005-03-07 Wyeth Corp Proceso para la sintesis de derivados de la 2,3-dihidro-1,4-dioxino-[2,3-f]-quinolina.
CA2450769A1 (en) 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US6903110B2 (en) 2001-07-25 2005-06-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
KR100894167B1 (ko) 2001-08-14 2009-04-22 토야마 케미칼 컴퍼니 리미티드 신규의 바이러스 증식저해 ·살바이러스방법 및 신규의피라진뉴클레오티드 ·피라진뉴클레오시드 유사체
US20040236110A1 (en) 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
WO2003031439A1 (en) 2001-10-05 2003-04-17 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003216660A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
US7429609B2 (en) 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
AU2002368154A1 (en) 2002-08-08 2004-02-25 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
JP3876265B2 (ja) 2003-02-26 2007-01-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ジヒドロプテリジノン、その製造方法及び薬物形態での使用
EP2295433A3 (en) 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
JP2007507529A (ja) 2003-09-30 2007-03-29 サイオス・インコーポレーテツド 複素環式アミドおよびスルホンアミド
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
AR049333A1 (es) 2004-04-02 2006-07-19 Vertex Pharma Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
KR100476851B1 (ko) 2004-05-18 2005-03-17 (주)성신엔지니어링 중력식 섬유여과기
JP2008503473A (ja) 2004-06-17 2008-02-07 プレキシコン，インコーポレーテッド Ｃ−ｋｉｔ活性を調節する化合物
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases
WO2006015123A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CN102766142A (zh) 2004-10-04 2012-11-07 千禧药品公司 有效作为蛋白激酶抑制剂的内酰胺化合物
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
PT1812440E (pt) 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
WO2006058120A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
EP1828180A4 (en) 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
US8101770B2 (en) 2004-12-16 2012-01-24 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
KR20070104641A (ko) 2005-02-03 2007-10-26 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로 유용한 피롤로피리미딘
RU2387653C2 (ru) 2005-05-16 2010-04-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназ
EP2354140A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
ZA200802685B (en) 2005-09-30 2009-10-28 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
WO2007059219A1 (en) 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
US20130096302A1 (en) 2005-11-22 2013-04-18 Hayley Binch Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
UA95940C2 (uk) 2006-01-17 2011-09-26 Вертекс Фармасьютикалс Інкорпорейтед Азаіндоли як інгібітори кіназ януса
US7622463B2 (en) 2006-02-14 2009-11-24 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
WO2007095223A2 (en) 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
SG170828A1 (en) 2006-04-05 2011-05-30 Vertex Pharmaceuticals Inc Us Deazapurines useful as inhibitors of janus kinases
KR20090021155A (ko) 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
WO2007146057A2 (en) 2006-06-09 2007-12-21 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
EP2050749B1 (en) 2006-08-08 2017-11-22 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as pi3k inhibitor and use thereof
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US20130310418A1 (en) 2006-11-15 2013-11-21 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
CN101646671A (zh) 2006-12-14 2010-02-10 弗特克斯药品有限公司 用作蛋白激酶抑制剂的化合物
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
EP2137183B1 (en) 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
EP2134709A1 (en) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridines useful as inhibitors of protein kinases
AU2008226457B2 (en) 2007-03-09 2014-03-20 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
AU2008228303B2 (en) 2007-03-22 2012-04-19 Takeda Pharmaceutical Company Limited Substituted pyrimidodiazepines useful as PLK1 inhibitors
UA98324C2 (ru) 2007-04-05 2012-05-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1H-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
NZ582879A (en) 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
AU2008287339A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases
PL2205603T3 (pl) 2007-09-28 2014-07-31 Cyclacel Ltd Pochodne pirymidyny jako inhibitory kinaz białkowych
EP2197901B1 (en) 2007-10-09 2013-12-11 European Molecular Biology Laboratory (Embl) Soluble fragments of influenza virus pb2 protein capable of binding rna-cap
TW200924762A (en) 2007-11-02 2009-06-16 Vertex Pharma Kinase inhibitors
CN101910150B (zh) 2007-11-05 2013-09-18 诺瓦提斯公司 作为cetp抑制剂、可用于治疗疾病如高脂血症或动脉硬化的4-苄基氨基-1-羧基酰基哌啶衍生物
JP5368485B2 (ja) 2008-02-25 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼインヒビター
JP2011513483A (ja) 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
WO2009125395A1 (en) 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti influenza antibodies and uses thereof
AU2009271658B2 (en) 2008-06-23 2014-04-10 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
MX2011000021A (es) 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011000843A (es) 2008-07-23 2011-04-11 Vertex Pharma Inhibidores de pirazolopiridin cinasa triciclicos.
ES2402087T3 (es) 2008-07-23 2013-04-26 Vertex Pharmaceuticals Incorporated Inhibidores de la pirazolopiridina quinasa
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
EP2321318A1 (en) 2008-07-23 2011-05-18 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
CA2760705A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
LT3141252T (lt) 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
JP5685895B2 (ja) * 2009-12-11 2015-03-18 株式会社リコー 画像処理装置、画像処理方法およびプログラム
HRP20160682T1 (hr) 2010-04-07 2016-07-29 Vertex Pharmaceuticals Incorporated Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
KR20130094710A (ko) 2010-04-14 2013-08-26 어레이 바이오파마 인크. Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
WO2011137022A1 (en) 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
CN103562205A (zh) 2010-12-16 2014-02-05 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
CA2822059A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
NZ714502A (en) 2011-07-05 2017-04-28 Vertex Pharma Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
MX2014005565A (es) 2011-11-07 2014-05-30 Vertex Pharma Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos.
EP2858984A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
MX377396B (es) 2013-09-12 2025-03-10 Janssen Biopharma Inc Compuestos de azapiridona y usos de los mismos.
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
EP3068434A1 (en) 2013-11-13 2016-09-21 Vertex Pharmaceuticals Inc. Formulations of azaindole compounds
JP6618901B2 (ja) 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
CN106573920B (zh) 2014-08-08 2020-11-10 爱尔兰詹森科学公司 用于在流感病毒感染中使用的吲哚
ES2860688T3 (es) 2014-09-08 2021-10-05 Janssen Sciences Ireland Uc Pirrolopirimidinas para uso en la infección por el virus de la gripe
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6903658B2 (ja) 2015-11-27 2021-07-14 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー インフルエンザウィルス感染に使用するための複素環インドール
DK3400225T3 (da) 2016-01-07 2022-01-03 Janssen Sciences Ireland Unlimited Co Pentansyrederivater substitueret med pyrrolo-[2,3-b]pyrimidinpyridiner til behandling af influenzavirusinfektioner
MX381314B (es) 2016-01-20 2025-03-12 Janssen Sciences Ireland Uc Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
WO2018191475A1 (en) 2017-04-12 2018-10-18 Vertex Pharmaceuticals Incorporated Combination therapies for treating influenza virus infection

Also Published As

Publication number Publication date
US20180155342A1 (en) 2018-06-07
CY1118726T1 (el) 2017-07-12
CN105503862A (zh) 2016-04-20
NZ716783A (en) 2017-08-25
EP3147284A1 (en) 2017-03-29
IN2014CN00562A (https=) 2015-04-03
TW201629061A (zh) 2016-08-16
CN105503862B (zh) 2018-02-02
GEP201606531B (en) 2016-08-25
CN103764654A (zh) 2014-04-30
AU2016228190B2 (en) 2018-11-08
GEP201706698B (en) 2017-07-10
JP6259855B2 (ja) 2018-01-10
NZ620086A (en) 2016-05-27
LT2739623T (lt) 2017-04-10
TWI594997B (zh) 2017-08-11
SG10201503833SA (en) 2015-06-29
JP5917692B2 (ja) 2016-05-18
CO6940412A2 (es) 2014-05-09
MX2014001067A (es) 2014-03-27
PH12014500257A1 (en) 2017-04-07
KR101967172B1 (ko) 2019-04-09
AU2012290127A1 (en) 2013-05-02
UA118010C2 (uk) 2018-11-12
PE20141209A1 (es) 2014-09-19
HK1223915A1 (zh) 2017-08-11
JP2014521688A (ja) 2014-08-28
UA122808C2 (uk) 2021-01-06
ME02638B (me) 2017-06-20
ES2763535T3 (es) 2020-05-29
TWI619715B (zh) 2018-04-01
EP3147284B1 (en) 2019-09-25
AP3867A (en) 2016-10-31
US9908878B2 (en) 2018-03-06
TW201738241A (zh) 2017-11-01
MX339149B (es) 2016-05-13
UY34234A (es) 2013-02-28
ZA201409246B (en) 2016-05-25
US20150191468A1 (en) 2015-07-09
CL2014000245A1 (es) 2014-08-18
US9394302B2 (en) 2016-07-19
HRP20170421T1 (hr) 2017-06-02
ES2618919T3 (es) 2017-06-22
AP2014007402A0 (en) 2014-01-31
KR20140064812A (ko) 2014-05-28
IL230618A0 (en) 2014-03-31
ECSP14013189A (es) 2014-11-28
AU2012290127B2 (en) 2016-10-27
EA201500265A1 (ru) 2015-10-30
CA2844054A1 (en) 2013-02-07
IL244597B (en) 2018-01-31
CA2844054C (en) 2020-09-01
EA201692506A3 (ru) 2017-10-31
CN103764654B (zh) 2016-01-20
EP2739623B1 (en) 2017-01-11
US9051319B2 (en) 2015-06-09
AR087418A1 (es) 2014-03-19
US20160355512A1 (en) 2016-12-08
JP2018062516A (ja) 2018-04-19
US20140094473A1 (en) 2014-04-03
SI2739623T1 (sl) 2017-07-31
WO2013019828A1 (en) 2013-02-07
HK1194736A1 (zh) 2014-10-24
JP2016121196A (ja) 2016-07-07
HK1223914A1 (zh) 2017-08-11
IL230618A (en) 2016-04-21
ZA201400604B (en) 2015-10-28
AU2016228190A1 (en) 2016-10-27
TWI537268B (zh) 2016-06-11
PT2739623T (pt) 2017-04-03
TW201313713A (zh) 2013-04-01
RS55858B1 (sr) 2017-08-31
DK2739623T3 (en) 2017-04-24
EA201490396A1 (ru) 2014-06-30
EA027210B1 (ru) 2017-06-30
EA201692506A2 (ru) 2017-06-30
IL244597A0 (en) 2016-04-21
SG10201503835TA (en) 2015-06-29
US10875855B2 (en) 2020-12-29
CN105481853A (zh) 2016-04-13
EA023423B1 (ru) 2016-06-30
HUE033752T2 (en) 2017-12-28
EA037372B1 (ru) 2021-03-22
EP2739623A1 (en) 2014-06-11
US20210040092A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
AP3867A (en) Inhibitors of influenza viruses replication
IL268366A (en) Inhibitors of viral replication
HRP20181715T1 (hr) Inhibitori replikacije virusa gripe
SI3068776T1 (sl) Inhibitorji replikacije virusov influence
IL245586A0 (en) Methods for preparing influenza virus reproduction suppressors
ZA201401665B (en) Viral replication inhibitors
GB201114891D0 (en) Novel viral replication inhibitors